A surgical technique called NeuroSafe almost doubles the chances that men will retain erectile function after prostate cancer surgery, according to the first large-scale clinical trial of the procedure. Results presented at the 2025 European Association of Urology congress in Madrid and published in Lancet Oncology offer real hope to the hundreds of thousands of men diagnosed with prostate cancer each year who face a painful trade-off between curing their cancer and preserving their quality of life.
At a glance
- NeuroSafe surgery: A technique where surgeons freeze and examine slices of prostate tissue mid-operation to confirm the tumor has been fully removed — allowing them to spare the surrounding nerve tissue if it’s safe to do so.
- Trial results: Among 344 men with no prior erectile dysfunction, only 38% of NeuroSafe patients reported severe erectile dysfunction one year after surgery, compared with 56% of men who received standard surgery.
- Erectile function outcomes: 39% of NeuroSafe patients reported no or only mild erectile dysfunction at one year, nearly double the 23% who reported the same after standard surgery.
How NeuroSafe prostate surgery works
The prostate is surrounded by a thin outer layer threaded with nerves believed to control erectile function. Standard surgery removes the prostate along with that layer to make sure no cancer cells are left behind — a cautious approach that often damages or destroys those nerves in the process.
NeuroSafe takes a different path. Surgeons remove the prostate and then immediately freeze, stain, and examine thin slices of the tissue while the patient is still on the operating table. If the tumor hasn’t reached the outer edge of the prostate, the nerve-containing layer can be left intact. If it has, surgeons remove it — but at least the decision is based on real-time evidence rather than estimation.
Professor Greg Shaw, the trial lead and a consultant urologist at University College London Hospitals NHS Foundation Trust, described the approach as giving surgeons “the certainty they need to spare as many nerves as possible and give men increased hope of recovering their sexual potency after their cancer is surgically removed.”
Why this matters for men with prostate cancer
Prostate cancer is the most common cancer in men in England, with 50,000 new cases diagnosed every year. Globally, nearly 1.5 million men are diagnosed annually and 375,000 die from the disease each year. It disproportionately affects men over 50 and is often detected late because it produces no symptoms in its early stages.
Surgery can be life-saving. But for many men, the prospect of permanent erectile dysfunction is a serious concern that shapes treatment decisions — sometimes leading men to delay or avoid surgery altogether. A technique that meaningfully reduces that risk without compromising cancer control could shift that calculation for a significant number of patients.
Advances in robotic-assisted surgery have already improved surgeons’ precision in prostate procedures, making nerve-sparing operations more feasible. NeuroSafe builds on that capability by adding an intraoperative feedback loop — a real-time tissue check — that removes much of the guesswork that previously forced surgeons toward more aggressive removal.
Part of a broader shift in cancer care
This trial fits into a wider pattern of cancer medicine moving toward treatments that don’t just extend life but protect how that life is lived. Research into precision surgical techniques has been reshaping what’s possible across multiple cancer types, and prostate cancer surgery is catching up.
The five hospitals involved in this trial are all NHS institutions, signaling that this isn’t just experimental medicine confined to private clinics. The Lancet Oncology publication gives the findings strong scientific standing, and the involvement of Prostate Cancer UK in evaluating the results adds credibility from the patient advocacy side.
What still needs to happen
Dr. Matthew Hobbs, director of research at Prostate Cancer UK, called the results promising but flagged key open questions: researchers still need to confirm that NeuroSafe is as effective as standard surgery at achieving a complete cure, and it’s not yet clear which patients are the best candidates for the technique.
The trial measured erectile function at one year, but the full picture of cure rates and recurrence will take more time and follow-up to establish. Rolling the procedure out at scale across the NHS would also present logistical and resourcing challenges that remain unresolved. The one-year results are encouraging; whether the nerve-sparing approach holds up over a decade is still an open question.
For now, though, the evidence is clear: a surgical technique that nearly doubles the odds of preserving erectile function — without requiring men to choose between cancer treatment and quality of life — is a meaningful advance worth watching closely.
Read more
For more on this story, see: The Independent
For more from Good News for Humankind, see:
- U.K. cancer death rates down to their lowest level on record
- Ghana expands marine protected areas at Cape Three Points
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Doctors hail first breakthrough in asthma and COPD treatment in 50 years
Benralizumab, a single injection given during an asthma or COPD attack, cut treatment failures fourfold over 90 days compared to the steroid pills doctors have relied on since the 1970s. In a trial of 158 patients arriving at UK emergency departments, the shot eased coughing, wheezing, and breathlessness more effectively than steroids — and could eventually be given at home or in a GP’s office. Because it targets the specific inflammation behind roughly half of asthma attacks, it could spare millions of people from the diabetes and bone-loss risks that come with repeated steroid use. After a 50-year wait for…
-
Mexico launches universal healthcare for all 133 million citizens
Mexico universal healthcare is now officially a reality, with the country launching a system designed to cover all 133 million citizens through the restructured IMSS-Bienestar network. Before this reform, an estimated 50 million Mexicans had no formal health insurance, with rural and Indigenous communities bearing the heaviest burden of untreated illness and medical debt. The new system severs the long-standing tie between employment and healthcare access, providing free consultations, medicines, and hospital services regardless of income. If implemented effectively, Mexico’s move could serve as a powerful model for other middle-income nations still navigating fragmented, inequitable health systems.
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana’s marine protected area — the country’s first ever — marks a historic turning point for a nation gripped by a quiet fisheries crisis. Established near Cape Three Points in the Western Region, the protected zone restricts or bans fishing activity to allow severely depleted fish populations to recover. Ghana’s coastal stocks have fallen by an estimated 80 percent from historic levels, threatening food security and the livelihoods of millions of small-scale fishers. The declaration also carries regional significance, potentially inspiring neighboring Gulf of Guinea nations to establish coordinated protections of their own.
